Reviewed by Peptide Treatments Medical Advisory Board (Medical Advisory Board)
Orforglipron: Evidence Summary
Evidence summary for Orforglipron across studied indications. Each indication is graded using our evidence tier system based on the quality and quantity of available clinical data.
Back to Orforglipron overview| Indication | Evidence Tier | Trial Count | Summary |
|---|---|---|---|
| Obesity / weight management | Tier B | 4 | Phase 3 ATTAIN-1 showed 9.4% weight loss at 36 mg; not yet FDA-approved |
| Type 2 diabetes (glycemic control) | Tier B | 4 | Phase 3 ATTAIN-2 showed 1.4% HbA1c reduction; not yet FDA-approved |
| Cardiovascular risk reduction | Tier D | 0 | No CVOT data available; outcomes trial expected completion 2027-2028 |
References (2)
- Orforglipron Phase 2 trial in type 2 diabetes — Wharton S, Blevins T, Connery L, et al. . New England Journal of Medicine (2023) PMID: 37369232
- Orforglipron Phase 2 trial in obesity — Frias JP, Hsia DS, Engel SS, et al. . New England Journal of Medicine (2023) PMID: 37351564